Gibson Dunn advises KKR on investment in Coriolis Pharma

Photo: The logo of Corio­lis Pharma (Image © Corio­lis Pharma)
16. Octo­ber 2023

Frank­furt, London and Munich — KKR Health Care Growth Fund II has made an invest­ment in German biophar­maceu­ti­cal rese­arch and deve­lo­p­ment company Corio­lis Pharma. As part of the tran­sac­tion, Corio­lis Pharma will enter into a stra­te­gic growth part­ner­ship with Fron­tier Bioso­lu­ti­ons, a global phar­maceu­ti­cal services plat­form newly formed by KKR and Flerie Invest AB.

KKR’s invest­ment will enable Corio­lis to embark on the next phase of growth in its core busi­ness, expand its port­fo­lio of services along the value chain, streng­then its global presence and conti­nue to inte­grate AI-based technologies.

Corio­lis is expec­ted to gain access to KKR’s global health­care network and Fron­tier Bioso­lu­ti­ons to expand Corio­lis’ global opera­ti­ons and growth plans in inno­va­tive, high-value formu­la­tion rese­arch and deve­lo­p­ment services.

“Since Corio­lis was foun­ded 15 years ago, our vision has been to revo­lu­tio­nize the biophar­maceu­ti­cal drug deve­lo­p­ment process by inte­gra­ting inno­va­tive digi­tal formu­la­tion approa­ches from deve­lo­p­ment through commer­cial products,” said Corio­lis co-foun­­ders and board members Michael and Thomas Wiggen­horn. The coope­ra­tion with KKR should enable major steps forward in this regard and further expand the company’s scien­ti­fic leader­ship posi­tion, he said.

The Gibson Dunn team, led by London part­ner and co-head of the private equity prac­tice in Europe Wim De Vlie­ger and Frank­furt part­ners Dr. Wilhelm Rein­hardt and Dr. Jan Schu­bert, included London coun­sel Dr. Jakob Egle and asso­cia­tes Sonja Rutt­mann, Dr. Dennis Seif­arth (both Munich), Lisa Holl­fel­der (Frank­furt) and Gisele Zouein (London). Brussels anti­trust and compe­ti­tion law part­ner Attila Borsos and London asso­cia­tes Ben Nunez and Robert Albert­son Kill as well as corpo­rate coun­sel Dr. Birgit Friedl and asso­ciate Dr. Marcus Geiss (both Munich) supported the team. In Munich, part­ner Kai Gesing and asso­cia­tes Chris­toph Jacob and Yannick Ober­acker advi­sed on IP issues, while Frank­furt finance coun­sel Alex­an­der Klein and asso­ciate Bastiaan Wolters advi­sed on finan­cing issues.

About Gibson Dunn

Gibson, Dunn & Crut­cher LLP is one of the leading inter­na­tio­nal law firms and is ranked among the top law firms world­wide in indus­try surveys and by autho­ri­ta­tive publi­ca­ti­ons. With more than 1,800 lawy­ers in 20 offices, the firm has a global presence in all major econo­mic regi­ons. Gibson Dunn offices are loca­ted in Abu Dhabi, Brussels, Century City, Dallas, Denver, Dubai, Frank­furt, Hong Kong, Hous­ton, London, Los Ange­les, Munich, New York, Orange County, Palo Alto, Paris, Beijing, San Fran­cisco, Singa­pore and Washing­ton, D.C. For more infor­ma­tion, visit

Subscribe newsletter

Here you can read about the latest transactions, IPOs, private equity deals and venture capital investments, who has raised a new fund, how Buy & Build activities are going.

Get in touch

Contact us!
fyb [at]